Tumor Vessel Development and Expansion in Ewing's Sarcoma: A Review of the Vasculogenesis Process and Clinical Trials with Vascular-Targeting Agents
2011

Understanding Blood Vessel Development in Ewing's Sarcoma

publication Evidence: moderate

Author Information

Author(s): Keri S. Stewart, Eugenie S. Kleinerman

Primary Institution: The University of Texas M. D. Anderson Cancer Center

Hypothesis

The study investigates the role of vasculogenesis in the growth of Ewing's sarcoma and the potential of targeting vascular development for treatment.

Conclusion

Vasculogenesis is essential for the growth of Ewing's sarcoma, and targeting VEGF and DLL4 may provide new therapeutic options.

Supporting Evidence

  • Ewing's sarcoma relies on a functional vascular supply formed by angiogenesis and vasculogenesis.
  • VEGF165 is a major chemotactic stimulant for recruiting bone marrow-derived cells to Ewing's tumors.
  • Inhibition of DLL4 significantly reduces the number of BM-derived pericytes/vSMCs and inhibits tumor growth.

Takeaway

Ewing's sarcoma needs blood vessels to grow, and scientists are looking for ways to stop these blood vessels from forming to help treat the cancer.

Methodology

The review summarizes current understanding of vasculogenesis in Ewing's sarcoma and discusses clinical trials using vascular-targeting agents.

Limitations

The review highlights the need for further studies to fully understand the molecular controls of vasculogenesis in Ewing's sarcoma.

Digital Object Identifier (DOI)

10.1155/2011/165837

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication